Qualitative flow metabolic phenotype of pancreatic cancer. A new prognostic biomarker?
HPB · 2024
DOI: 10.1016/j.hpb.2023.11.010 ↗Kurz gefasst
Fachartikel in der Zeitschrift HPB, 2024. Verfasst von Deniece Riviere und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Imaging, Radboud University Medical Center, Nijmegen, the Netherlands. Electronic address: D.Riviere@radboudumc.nl. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
BACKGROUND: Retrospective analysis to investigate the relationship between the flow-metabolic phenotype and overall survival (OS) of pancreatic ductal adenocarcinoma (PDAC) and its potential clinical utility. METHODS: Patients with histopathologically proven PDAC between 2005 and 2014 using tumor attenuation on routine pre-operative CECT as a surrogate for the vascularity and [18F]FDG-uptake as a surrogate for metabolic activity on [18F]FDG-PET. RESULTS: In total, 93 patients (50 male, 43 female, median age 63) were included. Hypoattenuating PDAC with high [18F]FDG-uptake has the poorest prognosis (median OS 7 ± 1 months), compared to hypoattenuating PDAC with low [18F]FDG-uptake (median OS 11 ± 3 months; p = 0.176), iso- or hyperattenuating PDAC with high [18F]FDG-uptake (median OS 15 ± 5 months; p = 0.004) and iso- or hyperattenuating PDAC with low [18F]FDG-uptake (median OS 23 ± 4 months; p = 0.035). In multivariate analysis, surgery combined with tumor differentiation, tumor stage, systemic therapy and flow metabolic phenotype remained independent predictors for overall survival. DISCUSSION: The novel qualitative flow-metabolic phenotype of PDAC using a combination of CECT and [18F]FDG-PET features, predicted significantly worse survival for hypoattenuating-high uptake pancreatic cancers compared to the other phenotypes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medical Imaging, Radboud University Medical Center, Nijmegen, the Netherlands. Electronic address: D.Riviere@radboudumc.nl.
- Department of Medical Imaging, Radboud University Medical Center, Nijmegen, the Netherlands.
- Department of Gastroenterology, Radboud University Medical Center, Nijmegen, the Netherlands.
- Wolfson Wohl Cancer Research Centre, School of Cancer Sciences, University of Glasgow, Bearsden, Glasgow, Scotland, United Kingdom; West of Scotland Pancreatic Unit, Glasgow Royal Infirmary, Glasgow, Scotland, United Ki…
- Department of Radiology, Leiden University Medical Center, Leiden, the Netherlands.
- Department of Pathology, Radboud University Medical Center, Nijmegen, the Netherlands; Department of Pathology, University Medical Center Utrecht, Utrecht, the Netherlands.
Zitieren
APA
Riviere, D., Aarntzen, E., van Geenen, E., Chang, D., de Geus-Oei, L. F., Brosens, L., van Laarhoven, K., Gotthardt, M., & Hermans, J. (2024). Qualitative flow metabolic phenotype of pancreatic cancer. A new prognostic biomarker?. HPB. https://doi.org/10.1016/j.hpb.2023.11.010
Vancouver
Riviere D, Aarntzen E, van Geenen E, Chang D, de Geus-Oei LF, Brosens L, et al. Qualitative flow metabolic phenotype of pancreatic cancer. A new prognostic biomarker?. HPB. 2024. doi:10.1016/j.hpb.2023.11.010
BibTeX
@article{Riviere2024,
author = {Riviere, Deniece and Aarntzen, Erik and van Geenen, Erwin and Chang, David and de Geus-Oei, Lioe-Fee and Brosens, Lodewijk and van Laarhoven, Kees and Gotthardt, Martin and Hermans, John},
title = {Qualitative flow metabolic phenotype of pancreatic cancer. A new prognostic biomarker?},
journal = {HPB},
year = {2024},
doi = {10.1016/j.hpb.2023.11.010}
}
EUVIMED